GlassScriptPhysician profile
Rajinder K Sahi
NPI 1124218854
$1,659.53
in general payments reported to CMS, 2019-2025
23 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $16.45 · 2021: $16.63 · 2023: $417 · 2024: $428 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.87 | 2023-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $238.32 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $169.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $166.60 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $155.44 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Shield Therapeutics INC | $82.68 | 2025 | |
| Amgen INC. | $55.62 | 2019 | |
| Nestle Healthcare Nutrition INC. | $49.93 | 2023 | |
| Scpharmaceuticals INC. | $37.25 | 2025 | |
| Merck Sharp & Dohme LLC | $31.12 | 2019-2025 | Capvaxive, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $26.84 | 2024 | Rexulti |
| Pfizer INC. | $25.65 | 2019-2024 | |
| Medtronic, INC. | $24.36 | 2025 | Inceptiv |
| Boston Scientific Corporation | $24.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.77 | 2023 | Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $17.46 | 2025 | Unithroid |
| Inspire Medical Systems, INC. | $17.38 | 2023 | Inspire |
| Tactile Systems Technology INC | $16.04 | 2023 | Entre Plus, Flexitouch Plus |
| Daiichi Sankyo INC. | $15.05 | 2019 | |
| Aimmune Therapeutics, INC. | $14.87 | 2025 | Zenpep |
| Amarin Pharma, INC. | $14.71 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.09 | 2023 | Onpattro |
| Currax Pharmaceuticals LLC | $13.63 | 2023 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajinder Sahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.